CEACAM5 and medullary thyroid gland carcinoma: In an initial phase I trial of an anti-CEA hMN-14 x m734 bispecific antibody (BsMAb) and I-131 di-diethylenetriamine pentaacetic acid (DTPA)-indium hapten, 9 MTC patients were enrolled, and another 29 in a phase II trial later on (82).